Avantor, Inc. $AVTR Shares Newly Purchased by True Freedom Investing LLC

True Freedom Investing LLC purchased a new position in shares of Avantor, Inc. (NYSE:AVTR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 39,010 shares of the company’s stock, valued at approximately $587,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP purchased a new position in shares of Avantor during the 2nd quarter worth $800,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Avantor during the second quarter worth $805,000. Freestone Grove Partners LP acquired a new stake in shares of Avantor during the second quarter worth $56,577,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Avantor in the second quarter valued at $1,922,000. Finally, Assenagon Asset Management S.A. grew its position in shares of Avantor by 425.0% in the second quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock valued at $5,513,000 after purchasing an additional 450,801 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AVTR shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $17.00 price target on shares of Avantor in a research note on Thursday. TD Cowen lifted their target price on Avantor from $15.00 to $17.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price target on the stock in a research note on Wednesday, July 29th. Robert W. Baird raised their price objective on Avantor from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Wells Fargo & Company lifted their price objective on Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $14.77.

Avantor Stock Performance

Shares of Avantor stock opened at $16.05 on Monday. The firm has a market cap of $10.87 billion, a PE ratio of 32.09, a price-to-earnings-growth ratio of 7.26 and a beta of 0.94. The firm’s 50-day simple moving average is $15.49 and its 200-day simple moving average is $11.24. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.27 and a current ratio of 1.89. Avantor, Inc. has a 1 year low of $7.26 and a 1 year high of $17.45.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, October 28th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.64 billion. Avantor had a return on equity of 9.79% and a net margin of 5.08%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period last year, the firm earned $0.22 earnings per share. Equities analysts forecast that Avantor, Inc. will post 0.82 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.